Special Considerations in the Care of Women With Advanced Heart Failure

Imo A. Ebong; Ersilia M. DeFilippis; Eman A. Hamad; Eileen M. Hsich; Varinder K. Randhawa; Filio Billia; Mahwash Kassi; Anju Bhardwaj; Mirnela Byku; Mrudala R. Munagala; Roopa A. Rao; Amy E. Hackmann; Claudia G. Gidea; Teresa DeMarco; Shelley A. Hall

doi:10.3389/fcvm.2022.890108

Special Considerations in the Care of Women With Advanced Heart Failure

Imo A. Ebong, Ersilia M. DeFilippis, Eman A. Hamad, Eileen M. Hsich, Varinder K. Randhawa, Filio Billia, Mahwash Kassi, Anju Bhardwaj, Mirnela Byku, Mrudala R. Munagala, Roopa A. Rao, Amy E. Hackmann, Claudia G. Gidea, Teresa DeMarco, Shelley A. Hall

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Advanced heart failure (AHF) is associated with increased morbidity and mortality, and greater healthcare utilization. Recognition requires a thorough clinical assessment and appropriate risk stratification. There are persisting inequities in the allocation of AHF therapies. Women are less likely to be referred for evaluation of candidacy for heart transplantation or left ventricular assist device despite facing a higher risk of AHF-related mortality. Sex-specific risk factors influence progression to advanced disease and should be considered when evaluating women for advanced therapies. The purpose of this review is to discuss the role of sex hormones on the pathophysiology of AHF, describe the clinical presentation, diagnostic evaluation and definitive therapies of AHF in women with special attention to pregnancy, lactation, contraception and menopause. Future studies are needed to address areas of equipoise in the care of women with AHF.

Original language	English (US)
Article number	890108
Pages (from-to)	890108
Journal	Frontiers in cardiovascular medicine
Volume	9
DOIs	https://doi.org/10.3389/fcvm.2022.890108
State	Published - Jul 11 2022

Keywords

advanced heart failure
advanced therapies (ATs)
heart transplant
ventricular assist device
women

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.3389/fcvm.2022.890108

Cite this

Ebong, I. A., DeFilippis, E. M., Hamad, E. A., Hsich, E. M., Randhawa, V. K., Billia, F., Kassi, M., Bhardwaj, A., Byku, M., Munagala, M. R., Rao, R. A., Hackmann, A. E., Gidea, C. G., DeMarco, T., & Hall, S. A. (2022). Special Considerations in the Care of Women With Advanced Heart Failure. Frontiers in cardiovascular medicine, 9, 890108. Article 890108. https://doi.org/10.3389/fcvm.2022.890108

@article{313778c15257490da7ec24f23f611370,

title = "Special Considerations in the Care of Women With Advanced Heart Failure",

abstract = "Advanced heart failure (AHF) is associated with increased morbidity and mortality, and greater healthcare utilization. Recognition requires a thorough clinical assessment and appropriate risk stratification. There are persisting inequities in the allocation of AHF therapies. Women are less likely to be referred for evaluation of candidacy for heart transplantation or left ventricular assist device despite facing a higher risk of AHF-related mortality. Sex-specific risk factors influence progression to advanced disease and should be considered when evaluating women for advanced therapies. The purpose of this review is to discuss the role of sex hormones on the pathophysiology of AHF, describe the clinical presentation, diagnostic evaluation and definitive therapies of AHF in women with special attention to pregnancy, lactation, contraception and menopause. Future studies are needed to address areas of equipoise in the care of women with AHF.",

keywords = "advanced heart failure, advanced therapies (ATs), heart transplant, ventricular assist device, women",

author = "Ebong, {Imo A.} and DeFilippis, {Ersilia M.} and Hamad, {Eman A.} and Hsich, {Eileen M.} and Randhawa, {Varinder K.} and Filio Billia and Mahwash Kassi and Anju Bhardwaj and Mirnela Byku and Munagala, {Mrudala R.} and Rao, {Roopa A.} and Hackmann, {Amy E.} and Gidea, {Claudia G.} and Teresa DeMarco and Hall, {Shelley A.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Ebong, DeFilippis, Hamad, Hsich, Randhawa, Billia, Kassi, Bhardwaj, Byku, Munagala, Rao, Hackmann, Gidea, DeMarco and Hall.",

year = "2022",

month = jul,

day = "11",

doi = "10.3389/fcvm.2022.890108",

language = "English (US)",

volume = "9",

pages = "890108",

journal = "Frontiers in cardiovascular medicine",

issn = "2297-055X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Special Considerations in the Care of Women With Advanced Heart Failure

AU - Ebong, Imo A.

AU - DeFilippis, Ersilia M.

AU - Hamad, Eman A.

AU - Hsich, Eileen M.

AU - Randhawa, Varinder K.

AU - Billia, Filio

AU - Kassi, Mahwash

AU - Bhardwaj, Anju

AU - Byku, Mirnela

AU - Munagala, Mrudala R.

AU - Rao, Roopa A.

AU - Hackmann, Amy E.

AU - Gidea, Claudia G.

AU - DeMarco, Teresa

AU - Hall, Shelley A.

PY - 2022/7/11

Y1 - 2022/7/11

N2 - Advanced heart failure (AHF) is associated with increased morbidity and mortality, and greater healthcare utilization. Recognition requires a thorough clinical assessment and appropriate risk stratification. There are persisting inequities in the allocation of AHF therapies. Women are less likely to be referred for evaluation of candidacy for heart transplantation or left ventricular assist device despite facing a higher risk of AHF-related mortality. Sex-specific risk factors influence progression to advanced disease and should be considered when evaluating women for advanced therapies. The purpose of this review is to discuss the role of sex hormones on the pathophysiology of AHF, describe the clinical presentation, diagnostic evaluation and definitive therapies of AHF in women with special attention to pregnancy, lactation, contraception and menopause. Future studies are needed to address areas of equipoise in the care of women with AHF.

AB - Advanced heart failure (AHF) is associated with increased morbidity and mortality, and greater healthcare utilization. Recognition requires a thorough clinical assessment and appropriate risk stratification. There are persisting inequities in the allocation of AHF therapies. Women are less likely to be referred for evaluation of candidacy for heart transplantation or left ventricular assist device despite facing a higher risk of AHF-related mortality. Sex-specific risk factors influence progression to advanced disease and should be considered when evaluating women for advanced therapies. The purpose of this review is to discuss the role of sex hormones on the pathophysiology of AHF, describe the clinical presentation, diagnostic evaluation and definitive therapies of AHF in women with special attention to pregnancy, lactation, contraception and menopause. Future studies are needed to address areas of equipoise in the care of women with AHF.

KW - advanced heart failure

KW - advanced therapies (ATs)

KW - heart transplant

KW - ventricular assist device

KW - women

UR - http://www.scopus.com/inward/record.url?scp=85134637432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134637432&partnerID=8YFLogxK

U2 - 10.3389/fcvm.2022.890108

DO - 10.3389/fcvm.2022.890108

M3 - Review article

C2 - 35898277

AN - SCOPUS:85134637432

SN - 2297-055X

VL - 9

SP - 890108

JO - Frontiers in cardiovascular medicine

JF - Frontiers in cardiovascular medicine

M1 - 890108

ER -

Special Considerations in the Care of Women With Advanced Heart Failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this